Is Elanco Animal Health Incorporated (ELAN) Positioned for Long-Term Growth With Seven Potential Blockbuster Launches?
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts
Elanco Animal Health Incorporated (NYSE:ELAN) is among the best healthcare stocks. TheFly reported on June 18 that TD Cowen analyst Steve Scala increased the price target on ELAN to $32 from $31 while maintaining a Buy rating on the shares. The firm highlighted seven potential blockbuster product launches as important drivers for future revenue growth and margin improvement.
TD Cowen noted that these upcoming launches, combined with ELAN’s diversified portfolio and leading position in pet retail, could support long-term growth, including projected revenue expansion of more than 5% and earnings per share growth of approximately 10% through 2032. Furthering its commitment to long-term category leadership, on June 18, Elanco Animal Health Incorporated (NYSE:ELAN) announced plans to launch Elanco Ventures, a corporate venture capital initiative focused on supporting and investing in innovation within the animal health industry. The platform will receive a $25 million multi-year commitment and will target early-stage companies developing therapeutic solutions and enabling technologies.